Company(ies): Bavarian Nordic, Pharmexa, Affitech
Principal Therapy Area: Cancer
£195 / $340 / €245
Online, PDF
MVA-BN-HER2 is viral vector/DNA vaccine based on the HER2/neu oncogene. The MVA-BN viral vector has been engineered to express the extracellular fragment of human HER2.
The viral vector, MVA-BN, has been shown to induce both a strong cellular as well as humoral (antibody) immune response. It can be applied safely and repeatedly in cases where follow-up vaccinations might be required, such as is the practice with therapeutic vaccines.
Use this Cancer Drug Futures report to analyse key drivers and dampeners of success
An extensive review of the factors which can affect this product's clinical and commercial performance. Each drug report provides and covers…
What you get
A copy of the Cancer Drug Futures report(s) in print or pdf as you wish
Are you interested in more than one product, indication or therapy area?
Why not build a specific drug futures library and save money!
We appreciate that some customers will need to review many products. That is why, if you buy more than 5 Cancer Drug Futures reports of your choice, we can arrange
Cost-effective collections
Customers focussing on specific disease areas can benefit from buying our cost-effective Cancer Drug Futures collections. Collections are available for the following cancer sectors:
For further information on the products covered, discounts, distribution or a demonstration, please click on the link for direct_sales@espicom.com